1832 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 5
Brief Articles
Chong, K. T.; Hinshaw, R. R.; Howe, W. J.; Finzel, B. C.;
Watenpaugh, K. D. Structure-based design of HIV protease inhibi-
tors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic
inhibitors. J. Med. Chem. 1996, 39, 4630-4642.
(24) Ersmark, K.; Larhed, M.; Wannberg, J. Microwave-enhanced me-
dicinal chemistry: A high-speed opportunity for convenient prepara-
tion of protease inhibitors. Curr. Opin. Drug DiscoVery DeVel. 2004,
7, 417-427.
(10) Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.;
Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich,
P. K.; Bohanon, M. J.; Horng, M.-M.; Lynn, J. C.; Chong, K.;
Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thais-
rivongs, S. Tipranavir (PNU-140690): A potent, orally bioavailable
nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-
pyrone sulfonamide class. J. Med. Chem. 1998, 41, 3467-3476.
(11) Rodr´ıguez-Barrios, F.; Gago, F. HIV protease inhibition: limited
recent progress and advances in understanding current pitfalls. Curr.
Top. Med. Chem. 2004, 4, 991-1007.
(12) Zhang, X.-Q.; Schooley, R. T.; Gerber, J. G. The effect of increasing
R1-acid glycoprotein concentration on the antiviral efficacy of human
immunodeficiency virus protease inhibitors. J. Infect. Dis. 1999, 180,
1833-1837.
(13) Acosta, E. P.; Kakuda, T. N.; Brundage, R. C.; Anderson, P. L.;
Fletcher, C. V. Pharmacodynamics of human immunodeficiency virus
type 1 protease inhibitors. Clin. Infect. Dis. 2000, 30, S151-S159.
(14) Fa¨ssler, A.; Bold, G.; Capraro, H.-G.; Cozens, R.; Mestan, J.;
Poncioni, B.; Ro¨sel, J.; Tintelnot-Blomley, M.; Lang, M. Aza-peptide
analogues as potent human immunodeficiency virus type-1 protease
inhibitors with oral bioavailability. J. Med. Chem. 1996, 39, 3203-
3216.
(25) Savin, V. I. N-Nitrenes. IV. Synthesis of unsymmetrical bibenzyls.
Zh. Org. Khim. 1992, 28, 43-50.
(26) Otteneder, M.; Plastaras, J. P.; Marnett, L. J. Reaction of malondi-
aldehyde-DNA adducts with hydrazines-development of a facile assay
for quantification of malondialdehyde equivalents in DNA. Chem.
Res. Toxicol. 2002, 15, 312-318.
(27) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions
of organoboron compounds. Chem. ReV. 1995, 95, 2457-2483.
(28) Espinet, P.; Echavarren, A. M. C-C coupling: The mechanisms of
the Stille reaction. Angew. Chem., Int. Ed. 2004, 43, 4704-4734.
(29) Sonogashira, K. In Handbook of Organopalladium Chemistry for
Organic Synthesis, Volume 1; Negishi, E.-i., Ed.; Wiley-Inter-
science: New York, 2002, p 493-530.
(30) Kappe, C. O.; Dallinger, D. The impact of microwave synthesis on
drug discovery. Nat. ReV. Drug DiscoVery 2006, 5, 51-63.
(31) No¨teberg, D.; Schaal, W.; Hamelink, E.; Vrang, L.; Larhed, M. High-
speed optimization of inhibitors of the malarial proteases plasmepsin
I and II. J. Comb. Chem. 2003, 5, 456-464.
(32) Gronowitz, S.; Bjoerk, P.; Malm, J.; Hoernfeldt, A.-B. The effect of
some additives on the Stille Pd0-catalyzed cross-coupling reaction.
J. Organomet. Chem. 1993, 460, 127-129.
(33) Alterman, M.; Andersson, H. O.; Garg, N.; Ahlsen, G.; Loevgren,
S.; Classon, B.; Danielson, U. H.; Kvarnstroem, I.; Vrang, L.; Unge,
T.; Samuelsson, B.; Hallberg, A. Design and fast synthesis of
C-terminal duplicated potent C2-symmetric P1/P1′-modified HIV-1
protease inhibitors. J. Med. Chem. 1999, 42, 3835-3844.
(34) Wannberg, J.; Kaiser, N.-F. K.; Vrang, L.; Samuelsson, B.; Larhed,
M.; Hallberg, A. High-speed synthesis of potent C2-symmetric HIV-1
protease inhibitors by in-situ aminocarbonylations. J. Comb. Chem.
2005, 7, 611-617.
(35) Balani, S. K.; Arison, B. H.; Mathai, L.; Kauffman, L. R.; Miller, R.
R.; Stearns, R. A.; Chen, I. W.; Lin, J. H. Metabolites of L-735,524,
a potent HIV-1 protease inhibitor, in human urine. Drug Metab.
Dispos. 1995, 23, 266-270.
(36) Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.;
Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.;
Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum
attenuates the activity of protease inhibitors toward wild-type and
mutant human immunodeficiency virus. Virology 1998, 250, 255-
262.
(37) Robinson, B. S.; Riccardi, K. A.; Gong, Y.-F.; Guo, Q.; Stock, D.
A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno,
R. J.; Lin, P.-F. BMS-232632, a highly potent human immunodefi-
ciency virus protease inhibitor that can be used in combination with
other available antiretroviral agents. Antimicrob. Agents Chemother.
2000, 44, 2093-2099.
(38) Pauletti, G. M.; Gangwar, S.; Siahaan, T. J.; Aube, J.; Borchardt, R.
T. Improvement of oral peptide bioavailability: Peptidomimetics and
prodrug strategies. AdV. Drug DeliVery ReV. 1997, 27, 235-256.
(39) Gray, R. A.; Vander Velde, D. G.; Burke, C. J.; Manning, M. C.;
Middaugh, C. R.; Borchardt, R. T. Delta-sleep-inducing peptide:
Solution conformational studies of a membrane-permeable peptide.
Biochemistry 1994, 33, 1323-1331.
(40) Conradi, R. A.; Hilgers, A. R.; Burton, P. S.; Hester, J. B. Epithelial
cell permeability of a series of peptidic HIV protease inhibitors:
aminoterminal substituent effects. J. Drug Target. 1994, 2, 167-171.
(15) Bold, G.; Fa¨ssler, A.; Capraro, H.-G.; Cozens, R.; Klimkait, T.;
Lazdins, J.; Mestan, J.; Poncioni, B.; Ro¨sel, J.; Stover, D.; Tintelnot-
Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.;
Hurlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.;
Lang, M. New aza-dipeptide analogues as potent and orally absorbed
HIV-1 protease inhibitors: candidates for clinical development. J.
Med. Chem. 1998, 41, 3387-3401.
(16) Robinson, B. S.; Riccardi, K. A.; Gong, Y.-F.; Guo, Q.; Stock, D.
A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno,
R. J.; Lin, P.-F. BMS-232632, a highly potent human immunodefi-
ciency virus protease inhibitor that can be used in combination with
other available antiretroviral agents. Antimicrob. Agents Chemother.
2000, 44, 2093-2099.
(17) Havlir, D. V.; O’Marro, S. D. Atazanavir: new option for treatment
of HIV infection. Clin. Infect. Dis. 2004, 38, 1599-1604.
(18) Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel,
S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; et al.
L-735, 524: an orally bioavailable human immunodeficiency virus
type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91,
4096-4100.
(19) Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare,
J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.;
Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald,
P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R.
L-735,524: The design of a potent and orally bioavailable HIV
protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
(20) Ekegren, J. K.; Unge, T.; Safa, M. Z.; Wallberg, H.; Samuelsson,
B.; Hallberg, A. A new class of HIV-1 protease inhibitors containing
a tertiary alcohol in the transition-state mimicking scaffold. J. Med.
Chem. 2005, 48, 8098-9102.
(21) Negishi, E.-i.; Ed. Handbook of Organopalladium Chemistry for
Organic Synthesis; Wiley-Interscience: New York, 2002; Volume
1.
(22) Larhed, M.; Moberg, C.; Hallberg, A. Microwave-accelerated
homogeneous catalysis in organic chemistry. Acc. Chem. Res. 2002,
35, 717-727.
(23) Larhed, M.; Hallberg, A. Microwave-assisted high-speed chemistry:
a new technique in drug discovery. Drug DiscoVery Today 2001, 6,
406-416.
JM051239Z